



Lilly's tirzepatide gives Novo Nordisk's semaglutide a run for the money in Phase 3 trial

By [Brian Buntz](#) | April 28, 2022




Eli Lilly and Co. (NYSE: LLY) has announced that tirzepatide enabled trial participants to lose up to 22.5% of their body weight in the SURMOUNT-1 study.

Study volunteers receiving tirzepatide lost up to 52 lb. (24 kg) in the 72-week Phase 3 trial. A total of 55% of those receiving a 10 mg dose lost at least 20% of their body weight while 63% of those on a 15 mg dose hit the same benchmark. Only 1.3% of those taking placebo had the same level of weight loss.

Tirzepatide is a glucose-dependent insulintropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor antagonist.

It is thus broadly similar to Novo Nordisk's semaglutide, a glucagon-like peptide 1 (GLP-1) receptor antagonist that has achieved strong growth in diabetes as Rybelsus. Demand appeared to be strong for Wegovy, an injectable semaglutide formulation that won FDA approval for supporting weight management in June 2021, but the **drug has faced supply challenges in the U.S.**

A report in **NEJM** found that semaglutide recipients on a reduced calorie diet lost 14.9% of their body weight after 68 weeks.



The tirzepatide molecule is a 39 amino acid linear peptide conjugated to a C20 fatty acid moiety. Tirzepatide image from Lilly.

Tirzepatide outperformed popular diabetes drugs in head-to-head clinical trials, **according to a GlobalData from 2021**

In Lilly's SURMOUNT-1 study, tirzepatide reached both co-primary endpoints related to mean percent change in body weight from baseline and weight loss of at least 5% relative to placebo.

"Obesity is a chronic disease that often does not receive the same standard of care as other conditions, despite its impact on physical, psychological and metabolic health, which can include increased risk of hypertension, heart disease, cancer and decreased survival," said Dr. Louis J. Aronne, investigator of SURMOUNT-1, in a news release. "Tirzepatide delivered impressive body weight reductions in SURMOUNT-1, which could represent an important step forward for helping the patient and physician partnership

treat this complex disease."

LLY shares ticked up 4% to \$297.27 after announcing the news. Novo Nordisk dipped by about 1% to \$110.19.

Lilly



EXPAND YOUR KNOWLEDGE AND STAY CONNECTED

Get the latest news and trends happening now in the drug discovery and development industry.

[GET THE NEWSLETTER](#)

MEDTECH 100 INDEX

MEDTECH 100
Market Summary > Current Price

\$75.10

August 5, 2025 at 8:10 PM UTC



The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

[CLICK FOR INDEX DETAILS >>](#)

Eli Lilly & Co.
Exhibit 2032
BPI Labs v. Eli Lilly
IPR2025-01346
Ex. 2032-001

treat this complex disease.”

LLY shares ticked up 4% to \$297.27 after announcing the news. Novo Nordisk dipped by about 1% to \$110.19.

Filed Under: [Metabolic disease/endocrinology](#)
Tagged With: [Eli Lilly and Co.](#), [semaglutide](#), [SURMOUNT-1](#), [Tirzepatide](#)

We recommend

Lilly's tirzepatide bests semaglutide in type 2 diabetes trial - Drug Discovery and Development

Brian Buntz, Drug Discovery and Development, 2021

Tirzepatide's potent efficacy in SURMOUNT-3 Trial

Brian Buntz, Drug Discovery and Development, 2023

Why Lilly's tirzepatide has blockbuster potential - Drug Discovery and Development

Brian Buntz, Drug Discovery and Development, 2021

Lilly wins FDA Fast Track for tirzepatide for weight comorbidities

Brian Buntz, Drug Discovery and Development, 2022

You searched for tirzepatide - Drug Discovery and Development

Brian Buntz, Drug Discovery and Development

New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation

Frontiers of Medicine, 2022

New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation

Frontiers of Medicine, 2022

Paracrine actions of glucagon-like peptide 1 in the gut unraveled

Camille Allard, Life Metabolism, 2022

Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translatio...

Liang Dai, Frontiers of Medicine, 2022

Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translatio...

Liang Dai, Frontiers of Medicine, 2022

Powered by **TREND MD**

ABOUT THE AUTHOR



Brian Buntz

As the pharma and biotech editor at WTW Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTW, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

RELATED ARTICLES



Sai Life Sciences exec: GLP-1 boom has 'exploded the peptide field' as firm opens new center



Lilly's oral GLP-1 achieves up to 1.6% A1C reduction and 16 lb weight loss in late-stage diabetes trial

Document title: Tirzepatide gives Novo Nordisk's semaglutide a run for the money in trial

Ex. 2032-002

Capture URL: <https://www.drugdiscoverytrends.com/lillys-tirzepatide-gives-novo-nordisks-semaglutide-a-run-for-the-money-in-phase-3-trial/>

Capture timestamp (UTC): Tue, 05 Aug 2025 21:01:26 GMT

Page 2 of 3

Comorbidities

Brian Buntz, Drug Discovery and Development, 2022

You searched for tirzepatide - Drug Discovery and Development

Brian Buntz, Drug Discovery and Development

Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translatio... [🔗](#)

Liang Dai, Frontiers of Medicine, 2022

Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translatio... [🔗](#)

Liang Dai, Frontiers of Medicine, 2022

Powered by **TREND** **MD**



ABOUT THE AUTHOR



Brian Buntz

As the pharma and biotech editor at WTW Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTW, he held the title of content director at Informa, where he focused on topics such as connected

devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.



RELATED ARTICLES

[READ MORE >](#)



Sai Life Sciences exec: GLP-1 boom has 'exploded the peptide field' as firm opens new center



Lilly's oral GLP-1 achieves up to 1.6% A1C reduction and 16 lb weight loss in late-stage diabetes trial



GLP-1 use tripled among non-diabetics, hitting \$5.8B in 2022



University of Ottawa students harness tobacco relative to grow Ozempic-like drugs

Connect with Drug Discovery & Development



DRUG
DISCOVERY & DEVELOPMENT_®

MASSDEVICE
DEVICETALKS
MEDTECH100 INDEX
MEDICAL DESIGN SOURCING
MEDICAL DESIGN & OUTSOURCING
MEDICAL TUBING + EXTRUSION

SUBSCRIBE TO OUR E-NEWSLETTER
CONTACT US
ABOUT US
R&D WORLD
DRUG DELIVERY BUSINESS NEWS
PHARMACEUTICAL PROCESSING WORLD